Purpose. With many preterm babies now surviving as a result of improvement in neonatal care in Nigeria, the incidence of visual impairment/blindness as a result of retinopathy of prematurity (ROP) may rise. We describe our findings after screening starts for the first time in a 15-year-old special care baby unit so as to establish the incidence and risk factors for developing ROP. Methods. A prospective study carried out at the Special Care Baby Unit (SCBU) and Pediatric Outpatient Clinics of the University of Port Harcourt Teaching Hospital between January 1 and October 31, 2012. Fifty-three preterm babies (of 550 neonates admitted within the study period) delivered before 32 completed weeks and weighing less than 1500？g were included in the study following informed consent and the main outcome measure was the development of any stage of ROP. Results. Mean gestational age at birth was weeks. Mean birth weight was ？g. Out of 550 babies admitted at SCBU, 87 of 100 preterms survived with 53 included in study. Twenty-five (47.2%) had different degrees of ROP with prevalence found to be 47.2%. Prevalence was higher (75%) in babies weighing 1300？g and those delivered before 30-week gestation (58%). Twenty-one (84%) had stage 1 no plus disease and 3 (12%) had stage 2 no plus disease. Only 1 (4%) had threshold disease in Zone 1. None had disease at stage 4 or 5 or AP-ROP. Receiving supplemental oxygen ( ; ), presence of sepsis ( ; ), multiple blood transfusions ( ; ), and delivery by caesarian section ( ; ) were significantly associated with development of ROP. There were no significant differences with gender, apneic spells, jaundice, or phototherapy. Conclusions and Relevance. All live infants with ROP were noted to regress spontaneously in this study. Though it may not be cost effective to acquire treatment facilities at the moment (the only child with treatable disease died), facilities for screening preterm infants displaying high risk features may be essential as smaller babies are saved. 1. Introduction The control of blindness in children is considered a high priority within the World Health Organization’s (WHO’s) VISION 2020—The Right to Sight programme [1]. Among the causes of blindness in children worldwide is retinopathy of prematurity (ROP). It is a disorder of the developing retinal vessels seen in premature infants, especially those weighing less than 1500？g or younger than 32-week gestational age at birth [2] that may or may not have received oxygen therapy in the neonatal unit [3]. It occurs from interruption of the normal progression of
References
[1]
C. Gilbert and A. Foster, “Childhood blindness in the context of VISION 2020—the right to sight,” Bulletin of the World Health Organization, vol. 79, no. 3, pp. 227–232, 2001.
[2]
S. E. Olitsky and L. B. Nelson, “Disorders of the eyes,” in Nelson Textbook of Pediatrics, R. E. Behrman, R. M. Kliegman, and H. B. Jenson, Eds., pp. 6588–6591, WB Saunders, Philadelphia, Pa, USA, 17th edition, 2003.
[3]
K. Campbell, “Intensive oxygen therapy as a possible cause for retrolental fibroplasia. A clinical approach,” Medical Journal of Australia, vol. 2, pp. 48–50, 1951.
[4]
F. L. Kretzer and H. M. Hittner, “Retinopathy of prematurity: clinical implications of retinal development,” Archives of Disease in Childhood, vol. 63, no. 10, pp. 1151–1167, 1988.
[5]
The Committee for the Classification of Retinopathy of Prematurity, “An international classification of retinopathy of prematurity,” Archives of Ophthalmology, vol. 102, pp. 1130–1134, 1984.
[6]
A. R. Fielder, D. E. Shaw, J. Robinson, and Y. K. Ng, “Natural history of retinopathy of prematurity: a prospective study,” Eye, vol. 6, part 3, pp. 233–242, 1992.
[7]
J. O'Sullivan, C. Gilbert, and A. Forster, “The causes of childhood blindness in South Africa,” South African Medical Journal, vol. 87, pp. 1691–1695, 1997.
[8]
S. Varughese, C. Gilbert, C. Pieper, and C. Cook, “Retinopathy of prematurity in South Africa: an assessment of needs, resources and requirements for screening programmes,” British Journal of Ophthalmology, vol. 92, no. 7, pp. 879–882, 2008.
[9]
B. J. Kushner and S. Sondheimer, “Medical treatment of glaucoma associated with cicatricial retinopathy of prematurity,” American Journal of Ophthalmology, vol. 94, no. 3, pp. 313–317, 1982.
[10]
R. Clemett and B. Darlow, “Results of screening low-birth-weight infants for retinopathy of prematurity,” Current Opinion in Ophthalmology, vol. 10, no. 3, pp. 155–163, 1999.
[11]
H. A. Ajibode, “Retinopathy of prematurity: a review,” Nigerian Journal of Paediatrics, vol. 31, no. 3, pp. 61–66, 2004.
[12]
“Retinopathy of prematurity: guidelines for screening and treatment. The report of a joint working party of the Royal College of Opthalmologists and the British Association of Perinatal Medicine,” Early Human Development, vol. 46, no. 3, pp. 239–258, 1996.
[13]
B. Ackerman, E. Sherwonit, and J. Williams, “Reduced incidental light exposure: effect on the development of retinopathy of prematurity in low birth weight infants,” Pediatrics, vol. 83, no. 6, pp. 958–962, 1989.
[14]
K. Csak, V. Szabo, A. Szabo, and A. Vannay, “Pathogenesis and genetic basis for retinopathy of prematurity,” Frontiers in Bioscience, vol. 11, no. 1, pp. 908–920, 2006.
[15]
M. Adekeye, Causes of blindness in children in NE Nigeria: a blind school study [Dissertation for Masters degree in Community eye health], Department of Preventive Ophthalmology, Institute of Ophthalmology, London, UK, 1996.
[16]
A. M. Baiyeroju-Agbeja and F. Omokhodion, “Screening for retinopathy of prematurity,” Nigerian Journal of Ophthalmology, vol. 6, no. 1, pp. 23–25, 1998.
[17]
Cryotherapy for Retinopathy of Prematurity Cooperative Group, “Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results,” Archives of Ophthalmology, vol. 106, pp. 471–479, 1988.
[18]
L. M. S. Dubowitz, V. Dubowitz, and C. Goldberg, “Clinical assessment of gestational age in the newborn infant,” The Journal of Pediatrics, vol. 77, no. 1, pp. 1–10, 1970.
[19]
International Committee for the Classification of Retinopathy of Prematurity, “The international classification of retinopathy of prematurity revisited: an international committee for the classification of retinopathy of prematurity,” Archives of Ophthalmology, vol. 123, no. 7, pp. 991–999, 2005.
[20]
S. Jalali, R. Anand, H. Kumar, M. R. Dogra, R. Azad, and L. Gopal, “Programme planning and screening strategy in retinopathy of prematurity,” Indian Journal of Ophthalmology, vol. 51, no. 1, pp. 89–99, 2003.
[21]
W. V. Good, “Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial,” Transactions of the American Ophthalmological Society, vol. 102, pp. 233–250, 2004.
[22]
T. L. Terry, “Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. I. Preliminary report,” American Journal of Ophthalmology, vol. 25, no. 2, pp. 203–204, 1942.
[23]
D. L. Phelps, “Retinopathy of prematurity: an estimate of vision loss in the United States—1979,” Pediatrics, vol. 67, no. 6, pp. 924–926, 1981.
[24]
A. H. A. A. Hakeem, G. B. Mohamed, and M. F. Othman, “Retinopathy of prematurity: a study of prevalence and risk factors,” Middle East African Journal of Ophthalmology, vol. 19, no. 3, pp. 289–294, 2012.
[25]
Y. Chen, X.-X. Li, H. Yin et al., “Risk factors for retinopathy of prematurity in six neonatal intensive care units in Beijing,” British Journal of Ophthalmology, vol. 92, no. 3, pp. 326–330, 2008.
[26]
N. Hussain, J. Clive, and V. Bhandari, “Current incidence of retinopathy of prematurity, 1989–1997,” Pediatrics, vol. 104, no. 3, p. e26, 1999.
[27]
E. Rowlands, A. C. W. Ionides, S. Chinn, H. Mackinnon, and C. C. Davey, “Reduced incidence of retinopathy of prematurity,” British Journal of Ophthalmology, vol. 85, no. 8, pp. 933–935, 2001.
[28]
P. M. Pennefather, W. Tin, M. P. Clarke, S. Fritz, and N. P. Strong, “Retinopathy of prematurity in a controlled trial of prophylactic surfactant treatment,” British Journal of Ophthalmology, vol. 80, no. 5, pp. 420–424, 1996.
[29]
J. Vyas, D. Field, E. S. Draper et al., “Severe retinopathy of prematurity and its association with different rates of survival in infants of less than 1251 g birth weight,” Archives of Disease in Childhood, vol. 82, no. 2, pp. F145–F149, 2000.
[30]
P.-M. Liu, P.-C. Fang, C.-B. Huang et al., “Risk factors of retinopathy of prematurity in premature infants weighing less than 1600 g,” American Journal of Perinatology, vol. 22, no. 2, pp. 115–120, 2005.
[31]
J. Stone, T. Chan-Ling, J. Pe'er, A. Itin, H. Gnessin, and E. Keshet, “Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity,” Investigative Ophthalmology and Visual Science, vol. 37, no. 2, pp. 290–299, 1996.
[32]
C. Clark, J. A. H. Gibbs, R. Maniello, E. W. Outerbridge, and J. V. Aranda, “Blood transfusion: a possible risk factor in retrolental fibroplasia,” Acta Paediatrica Scandinavica, vol. 70, no. 4, pp. 535–539, 1981.
[33]
L. M. Sacks, D. B. Schaffer, and E. K. Anday, “Retrolental fibroplasia and blood transfusion in very low-birth-weight infants,” Pediatrics, vol. 68, no. 6, pp. 770–774, 1981.
[34]
E. Mikaniki, M. Mikaniki, and A. H. Shirzadian, “Effects of blood transfusion on retinopathy of prematurity,” in Blood Transfusion in Clinical Practice, P. K. Kochhar, Ed., InTech, Vienna, Austria, 2012, http://www.intechopen.com/books/blood-transfusion-in-clinicalpractice/effects-of-blood-transfusion-on-retinopathy-of-prematurity.
[35]
V. A. Shah, C. L. Yeo, Y. L. F. Ling, and L. Y. Ho, “Incidence, risk factors of retinopathy of prematurity among very low birth weight infants in Singapore,” Annals of the Academy of Medicine Singapore, vol. 34, no. 2, pp. 169–178, 2005.
[36]
P. Manzoni, D. Farina, A. Maestri et al., “Mode of delivery and threshold retinopathy of prematurity in pre-term ELBW neonates,” Acta Paediatrica, International Journal of Paediatrics, vol. 96, no. 2, pp. 221–226, 2007.
[37]
V. Seiberth and O. Linderkamp, “Risk factors in retinopathy of prematurity: a multivariate statistical analysis,” Ophthalmologica, vol. 214, no. 2, pp. 131–135, 2000.
[38]
B. A. Darlow, J. L. Hutchinson, D. J. Henderson-Smart, D. A. Donoghue, J. M. Simpson, and N. J. Evans, “Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network,” Pediatrics, vol. 115, no. 4, pp. 990–996, 2005.
[39]
E. A. Palmer, J. T. Flynn, R. J. Hardy et al., “Incidence and early course of retinopathy of prematurity,” Ophthalmology, vol. 98, no. 11, pp. 1628–1640, 1991.
[40]
Cryotherapy for Retinopathy of Prematurity Cooperative Group, “The natural ocular outcome of premature birth and retinopathy: status at 1 year,” Archives of Ophthalmology, vol. 112, no. 7, pp. 903–912, 1994.
